Passive Immunity Trial for Our Nation (PassItOn)

About this Study

Effective therapies for COVID-19 are urgently needed. Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection. This plasma contains SARS-CoV-2 specific antibodies that may help patients with COVID-19 recover. Preliminary reports suggest potential efficacy in small human studies. Clinical trial data are needed to determine whether convalescent donor plasma is effective in treating COVID-19.

Sponsor Protocol ID:200738
IRB Number:2020V0245
Closed for Enrollment
Early Phase 1
September 14, 2020
Eligibility Criteria
18 years old
Both Male and Female

Inclusion Criteria
1. Age greater than or equal to 18 years of age
2. Currently hospitalized or in an emergency department with anticipated hospitalization
3. Symptoms of acute respiratory infection, defined as one or more of the following:
a. Cough
b. Chills, or a fever (greater than 37.5° C or 99.5° F)
c. Shortness of breath
4. Laboratory-confirmed SARS-CoV-2 infection within the past 14 days

Exclusion Criteria
1. Prisoner
2. Unable to randomize within 14 days after onset of acute respiratory infection symptoms
3. Patient, legal representative, or physician not committed to full support (Exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.)
4. Inability to be contacted on Day 29-36 for clinical outcome assessment
5. Plan for hospital discharge within 24 hours of enrollment
6. Previous enrollment in this trial
7. Enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy

Categories Click category to view its trials.
COVID-19 (Coronavirus)
Emergency Medicine
Participating Locations
Emergency Room (Adult) - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Rebekah Peacock
Phone Number: 601-815-3008
Principal Investigator:Jones, Alan E, M.D.
How to participate in our Clinical Trials